Lexeo director granted 35,000 stock options

Lexeo Therapeutics director Reinaldo M. Diaz received a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Lexeo Therapeutics director Reinaldo M. Diaz received a grant of stock options as equity compensation. He was awarded options to acquire 35,000 shares of common stock at an exercise price of $4.70 per share, with all shares underlying the option scheduled to vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, conditioned on his continuous service.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider DIAZ REINALDO M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 35,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Key Figures

Options granted: 35,000 options Exercise price: $4.70 per share Underlying shares: 35,000 shares +3 more

6 metrics

Options granted 35,000 options Stock Option (right to buy) covering common stock

Exercise price $4.70 per share Conversion or exercise price of the option

Underlying shares 35,000 shares Common stock underlying the derivative security

Post-transaction derivative holdings 35,000 options Total derivative shares following the transaction

Expiration date June 24, 2036 Option expiration for the reported grant

Transaction code A (grant/award acquisition) Indicates option grant as equity compensation

Key Terms

Stock Option (right to buy), grant/award acquisition, continuous service, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title is reported as Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action is listed as grant/award acquisition"

continuous service financial

"vesting is subject to the Reporting Person's continuous service"

annual meeting of stockholders regulatory

"vesting occurs by one year or the next annual meeting of stockholders"

exercise price financial

"conversion_or_exercise_price is disclosed as 4.7000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexeo Therapeutics (LXEO) director Reinaldo M. Diaz report on this Form 4?

He reported receiving a grant of stock options covering 35,000 shares of Lexeo Therapeutics common stock. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price if and when they vest and become exercisable.

How many Lexeo Therapeutics (LXEO) shares are covered by the new stock options?

The option grant covers 35,000 underlying shares of Lexeo Therapeutics common stock. This entire amount is tied to a single option award reported as a derivative security, with 35,000 shares shown as beneficially owned following the transaction.

What is the exercise price of the Lexeo Therapeutics (LXEO) stock options granted?

The options have an exercise price of $4.70 per share. This means Diaz can purchase Lexeo Therapeutics common stock at $4.70 per share once the options vest and become exercisable, regardless of the market price at that future time.

When do the newly granted Lexeo Therapeutics (LXEO) options vest and become exercisable?

All shares underlying the option vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Diaz’s continuous service through that date, as described in the footnote.

Are the Lexeo Therapeutics (LXEO) options held directly or indirectly by Reinaldo M. Diaz?

The filing shows the options as directly owned by Diaz. The ownership code is listed as “D” for direct ownership, and there is no footnote indicating that another entity or trust holds voting or investment power over these derivative securities.

When do the Lexeo Therapeutics (LXEO) stock options expire?

The options are scheduled to expire on June 24, 2036. After this expiration date, any portion of the option that has not been exercised will no longer be usable to purchase Lexeo Therapeutics common stock at the specified exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DIAZ REINALDO M

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)